"When the first BTK inhibitor got approved by the FDA for ... a gene called BCL2," Strati told MedPage Today, adding that in B-cell lymphomas with BCL2 translocation, the B-cell receptor is ...

AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...

"EC approves AstraZeneca’s Calquence combo to treat MCL" was originally created and published by Pharmaceutical Technology, a ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the 2025 American Society of ...

Cambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been ...

AstraZeneca’s Calquence plus chemoimmunotherapy approved in EU to treat adult patients with previously untreated mantle cell lymphoma: Cambridge, UK Wednesday, May 7, 2025, 09:0 ...

EMA committee recommends approval of AstraZeneca’s fixed-duration Calquence-based regimens for 1st-line chronic lymphocytic leukaemia: Cambridge, UK Wednesday, April 30, 2025, 1 ...

The authors explained that while molecularly targeted therapies like Bruton tyrosine kinase (BTK) inhibitors and B-cell leukemia/lymphoma-2 (BCL-2) inhibitors can target aberrant signaling ...

MALT1, a key protease in the NF-kB pathway, drives malignant B-cell proliferation in hematological cancers. While current therapies (e.g., BTK inhibitors) have advanced treatment, resistance ...

With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease ...